Julie Gerberding - Merck President
| MRK Stock | MXN 2,172 10.50 0.48% |
President
Dr. Julie Louise Gerberding, M.D. is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health of Merck Co., Inc. In this newly created Executive Committee position, Gerberding, who most recently served as president of Merck Vaccines, will be responsible for Mercks global public policy, corporate responsibility and communications functions, as well as the Merck Foundation and the Merck for Mothers program. Gerberding will also lead new partnership initiatives that accelerate Mercks ability to contribute to improved population health, a measure of impact that is increasingly valued by governments and other global health organizations. Gerberding joined Merck as president of Merck Vaccines in January 2010. Since then, Mercks vaccines are reaching more people than ever, and Merck became the global leader in the vaccine market based on sales. In addition, the Sanofi Pasteur MSD joint venture in Europe, Mercks European vaccine business for which Gerberding is the Board cochair, has improved in both population reach and financial performance. She also helped lead the successful launch in India of the Merck Wellcome Trust nonprofit joint venture for vaccine development, the MSD Wellcome Trust Hilleman Laboratories. Prior to joining Merck, Gerberding served as director of the U.S. Centers for Disease Control and Prevention from 20022009 and before that served as director of the Division of Healthcare Quality Promotion. Before joining the CDC, Gerberding was a tenured faculty member in Infectious Diseases at the University of California at San Francisco . She continues as an Adjunct Associate Clinical Professor of Medicine at UCSF. since 2016.
| Age | 62 |
| Tenure | 8 years |
| Phone | 908 740 4000 |
| Web | https://www.merck.com |
Julie Gerberding Latest Insider Activity
Tracking and analyzing the buying and selling activities of Julie Gerberding against Merck stock is an integral part of due diligence when investing in Merck. Julie Gerberding insider activity provides valuable insight into whether Merck is net buyers or sellers over its current business cycle. Note, Merck insiders must abide by specific rules, including filing SEC forms every time they buy or sell Merck'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Julie Gerberding over a year ago Afternext Healthtech exotic insider transaction detected |
Merck Management Efficiency
The company has return on total asset (ROA) of 0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.351 %, meaning that it generated $0.351 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Karen Linehan | Sanofi | 59 | |
| Paul Clancy | Biogen Inc | 53 | |
| Ameet Nathwani | Sanofi | N/A | |
| Murdo Gordon | Bristol Myers Squibb | 50 | |
| Melissa Barnes | Eli Lilly and | 50 | |
| Carsten Hellmann | Sanofi | 51 | |
| David Ricks | Eli Lilly and | 55 | |
| Anirvan Ghosh | Biogen Inc | N/A | |
| JeanBaptiste Chatillon | Sanofi | 58 | |
| Camille Lee | Biogen Inc | N/A | |
| Daniel Karp | Biogen Inc | 40 | |
| John Reed | Sanofi | 60 | |
| Stefan Oelrich | Sanofi | 49 | |
| Pascale Witz | Sanofi | N/A | |
| Cynthia Patton | Amgen Inc | 56 | |
| Dominique Carouge | Sanofi | N/A | |
| Adam Koppel | Biogen Inc | 45 | |
| Joshua Smiley | Eli Lilly and | 48 | |
| Peter Guenter | Sanofi | 54 | |
| Myles ONeill | Eli Lilly and | 59 | |
| Jeffrey Simmons | Eli Lilly and | 49 | |
Management Performance
| Return On Equity | 0.35 | |||
| Return On Asset | 0.13 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Glocer, Independent Director | ||
| Craig Thompson, Independent Director | ||
| Cristal Downing, Ex Officer | ||
| Jennifer Zachary, General Counsel | ||
| Rochelle Lazarus, Independent Director | ||
| Michael Rosenblatt, Executive Vice President Chief Medical Officer | ||
| Wendell Weeks, Independent Director | ||
| Michael Holston, Executive Vice President Chief Ethics and Compliance Officer | ||
| Paul Rothman, Director | ||
| Mary Coe, Director | ||
| Adele Ambrose, Senior Vice President Chief Communications Officer | ||
| Caroline Litchfield, Ex CFO | ||
| Joseph Romanelli, IR Contact Officer | ||
| Mirian GraddickWeir, Executive Vice President - Human Resources | ||
| Peter Wendell, Independent Director | ||
| John Noseworthy, Independent Director | ||
| Jennifer Mauer, VP Communications | ||
| Leslie Brun, Independent Director | ||
| Julie Gerberding, Executive Vice President - Strategic Communications, Global Public Policy & Population Health | ||
| Inge Thulin, Director | ||
| Pamela Craig, Director | ||
| Patricia Russo, Independent Director | ||
| David Williams, Ex Officer | ||
| Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division | ||
| Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller | ||
| Lisa LeCointeCephas, VP Officer | ||
| Robert Davis, CFO and Executive VP | ||
| Robert Kidder, Independent Director | ||
| Thomas Cech, Independent Director | ||
| Michael Nally, Chief Marketing Officer | ||
| Peter Dannenbaum, VP Relations | ||
| Clark Golestani, Executive Vice President CIO | ||
| William Harrison, Lead Independent Director | ||
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
| Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer | ||
| Steven Mizell, Chief Human Resource Officer | ||
| Jim Scholefield, Chief Information and Digital Officer | ||
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
| Adam Schechter, President of Global Human Health and Executive VP | ||
| Carlos Represas, Independent Director | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman, CEO and Pres | ||
| Frank Clyburn, Chief Commercial Officer | ||
| Robert JD, Pres Chairman |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.35 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.24 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 5.9 T | |||
| Shares Outstanding | 2.54 B | |||
| Shares Owned By Insiders | 0.10 % | |||
| Shares Owned By Institutions | 76.37 % | |||
| Price To Earning | 469.71 X | |||
| Price To Book | 6.28 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Merck in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Merck's short interest history, or implied volatility extrapolated from Merck options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |